PGNY

Progyny, Inc.

9 filings tracked

healthcarebiotechnologyMID ($2B-10B)

Signal Magnitude Chart

bullish

bearish

neutral

Signal Timeline

neutralMay 27

Governance changes make it easier to remove directors and amend bylaws.

management change

40%

bullishMay 27

Elimination of supermajority voting lowers the barrier for future M&A activity.

acquisition

70%

bullishMay 26

Authorization of $200 million share repurchase program to reduce share count.

buyback

70%

bullishMay 8

Gross margin expanded 190 basis points to 25.3% due to operational efficiencies.

margin expansion

90%

bullishMay 8

Completed $200 million share repurchase program, returning significant capital to shareholders.

buyback

70%

bullishMay 8

Net income surged 61% year-over-year to $24.2 million.

earnings beat

80%

bearishMay 8

Revenue growth remained nearly flat at 1%, indicating a potential growth plateau.

earnings miss

40%

bullishMay 8

Gross margin expanded 190 basis points to 25.3% due to operational efficiencies.

margin expansion

90%

bullishMay 8

Completed $200 million share repurchase program, returning significant capital to shareholders.

buyback

70%

bullishMay 8

Net income surged 61% year-over-year to $24.2 million.

earnings beat

80%

bearishMay 8

Revenue growth remained nearly flat at 1%, indicating a potential growth plateau.

earnings miss

40%

bullishMay 8

Gross margin expanded 190 basis points to 25.3% due to operational efficiencies.

margin expansion

90%

bullishMay 8

Completed $200 million share repurchase program, returning significant capital to shareholders.

buyback

70%

bullishMay 8

Net income surged 61% year-over-year to $24.2 million.

earnings beat

80%

bearishMay 8

Revenue growth remained nearly flat at 1%, indicating a potential growth plateau.

earnings miss

40%

bullishMay 8

Gross margin expanded 190 basis points to 25.3% due to operational efficiencies.

margin expansion

90%

bullishMay 8

Completed $200 million share repurchase program, returning significant capital to shareholders.

buyback

70%

bullishMay 8

Net income surged 61% year-over-year to $24.2 million.

earnings beat

80%

bearishMay 8

Revenue growth remained nearly flat at 1%, indicating a potential growth plateau.

earnings miss

40%

bullishMay 8

Gross margin expanded 190 basis points to 25.3% due to operational efficiencies.

margin expansion

90%

bullishMay 8

Completed $200 million share repurchase program, returning significant capital to shareholders.

buyback

70%

bullishMay 8

Net income surged 61% year-over-year to $24.2 million.

earnings beat

80%

bearishMay 8

Revenue growth remained nearly flat at 1%, indicating a potential growth plateau.

earnings miss

40%

bullishMay 8

Gross margin expanded 190 basis points to 25.3% due to operational efficiencies.

margin expansion

90%

bullishMay 8

Completed $200 million share repurchase program, returning significant capital to shareholders.

buyback

70%

bullishMay 8

Net income surged 61% year-over-year to $24.2 million.

earnings beat

80%

bearishMay 8

Revenue growth remained nearly flat at 1%, indicating a potential growth plateau.

earnings miss

40%

bullishMay 8

Gross margin expanded 190 basis points to 25.3% due to operational efficiencies.

margin expansion

90%

bullishMay 8

Completed $200 million share repurchase program, returning significant capital to shareholders.

buyback

70%

bullishMay 8

Net income surged 61% year-over-year to $24.2 million.

earnings beat

80%

bearishMay 8

Revenue growth remained nearly flat at 1%, indicating a potential growth plateau.

earnings miss

40%

Filing History

8-KMay 27, 2026

Progyny's 8-K filing confirms that stockholders have overwhelmingly approved amendments to the company's Certificate of Incorporation and Bylaws to eliminate supermajority voting requirements. While the move is framed as a strategic unlock for agility and M&A, it simultaneously strips away traditional anti-takeover protections. The outcome represents a pivot toward a more flexible corporate structure, leaving investors to weigh the benefits of accelerated strategic execution against the risks of reduced oversight and increased vulnerability to hostile actions.

8-KMay 26, 2026

The 8-K filing confirms a strategic shift in Progyny's financial management, introducing a $200 million buyback to optimize its capital structure. While the move provides an immediate valuation floor and aligns management with shareholders, it introduces a tension between immediate capital return and future growth investment. Investors must now weigh the benefit of reduced dilution against the potential risk of diminished liquidity in a competitive healthcare technology landscape.

10-QMay 8, 2026

The Q1 2026 filing presents a dichotomy between accounting-driven profitability and stagnant operational growth. On one hand, the company has successfully cleaned up its P&L, reducing stock-based compensation and leveraging its existing client base to drive a significant jump in net income and EPS. The completion of the share buyback program is a strong signal of management's belief in the stock's undervaluation and a commitment to returning capital to shareholders. However, the lack of meaningful top-line growth and the dip in ART cycle utilization raise questions about the long-term ceiling for the current model. Investors must determine if the margin expansion is a sustainable result of operational excellence or a one-time benefit from a shrinking cost base following the loss of a major client. The trade-off for investors is now between a disciplined, cash-returning value play and a growth story that appears to be hitting a plateau in its core service utilization.